Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron versus solifenacin in adults with overactive bladder dissatisfied with prior antimuscarinic efficacy
NL-OMON37799Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Mirabegron arm with Solifenacin arm (2 arms). Primary endpoint: Change from baseline in mean number of micturitions per 24 hours. Started Aug 2012; status: active, not recruiting.
02
Drugs
mirabegronsolifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON37799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37799.